ADMA Biologics Inc. (ADMA)
ADMA Biologics Statistics
Share Statistics
ADMA Biologics has 237.62M shares outstanding. The number of shares has increased by 2.5% in one year.
| Shares Outstanding | 237.62M |
| Shares Change (YoY) | 2.5% |
| Shares Change (QoQ) | 0.52% |
| Owned by Institutions (%) | 86.9% |
| Shares Floating | 229.31M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 13.53M, so 5.73% of the outstanding shares have been sold short.
| Short Interest | 13.53M |
| Short % of Shares Out | 5.73% |
| Short % of Float | 5.92% |
| Short Ratio (days to cover) | 5.63 |
Valuation Ratios
The PE ratio is 20.22 and the forward PE ratio is 23.43. ADMA Biologics's PEG ratio is -0.03.
| PE Ratio | 20.22 |
| Forward PE | 23.43 |
| PS Ratio | 9.37 |
| Forward PS | 4.8 |
| PB Ratio | 11.45 |
| P/FCF Ratio | 33.68 |
| PEG Ratio | -0.03 |
Enterprise Valuation
ADMA Biologics has an Enterprise Value (EV) of 3.98B.
| EV / Sales | 9.32 |
| EV / EBITDA | 26.92 |
| EV / EBIT | 33.51 |
| EV / FCF | 33.51 |
Financial Position
The company has a current ratio of 5.97, with a Debt / Equity ratio of 0.24.
| Current Ratio | 5.97 |
| Quick Ratio | 2.9 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 0.56 |
| Debt / FCF | 0.69 |
| Interest Coverage | 9.98 |
Financial Efficiency
Return on Equity is 56.64% and Return on Invested Capital is 50.31%.
| Return on Equity | 56.64% |
| Return on Assets | 40.45% |
| Return on Invested Capital | 50.31% |
| Revenue Per Employee | $622.56K |
| Profits Per Employee | $288.57K |
| Employee Count | 685 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 1.22 |
Taxes
| Income Tax | -71.96M |
| Effective Tax Rate | -57.24% |
Stock Price Statistics
The stock price has increased by 250.33% in the last 52 weeks. The beta is 0.53, so ADMA Biologics's price volatility has been higher than the market average.
| Beta | 0.53 |
| 52-Week Price Change | 250.33% |
| 50-Day Moving Average | 17.8 |
| 200-Day Moving Average | 17.25 |
| Relative Strength Index (RSI) | 60.86 |
| Average Volume (20 Days) | 2.82M |
Income Statement
In the last 12 months, ADMA Biologics had revenue of 426.45M and earned 197.67M in profits. Earnings per share was 0.85.
| Revenue | 426.45M |
| Gross Profit | 219.55M |
| Operating Income | 138.98M |
| Net Income | 197.67M |
| EBITDA | 147.69M |
| EBIT | 139.64M |
| Earnings Per Share (EPS) | 0.85 |
Balance Sheet
The company has 103.15M in cash and 82.12M in debt, giving a net cash position of 21.03M.
| Cash & Cash Equivalents | 103.15M |
| Total Debt | 82.12M |
| Net Cash | 21.03M |
| Retained Earnings | -308.58M |
| Total Assets | 488.68M |
| Working Capital | 275.87M |
Cash Flow
In the last 12 months, operating cash flow was 118.67M and capital expenditures 0, giving a free cash flow of 118.67M.
| Operating Cash Flow | 118.67M |
| Capital Expenditures | 0 |
| Free Cash Flow | 118.67M |
| FCF Per Share | 0.51 |
Margins
Gross margin is 51.48%, with operating and profit margins of 32.59% and 46.35%.
| Gross Margin | 51.48% |
| Operating Margin | 32.59% |
| Pretax Margin | 29.48% |
| Profit Margin | 46.35% |
| EBITDA Margin | 34.63% |
| EBIT Margin | 32.59% |
| FCF Margin | 27.83% |
Dividends & Yields
ADMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 4.95% |
| FCF Yield | 2.97% |
Analyst Forecast
The average price target for ADMA is $25, which is 19.3% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25 |
| Price Target Difference | 19.3% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 20.39 |
| Piotroski F-Score | 7 |